MOC News and Press, Command Security Corporation From 09/29/23

Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseases Completed successful Secondary Public Offering (SPO) of gross proceeds of approximately PLN50 ...

MONTREAL, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) is pleased to announce that, following a recent compilation of all historical drilling data on the Amanda project , the Company traced the presence o...

MONTREAL, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “the Company”) is pleased to announce the start of prospecting work on the Lithium SM project after several weeks of delays caused by forest fires. Covering 10,864 h...

MONTREAL, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “the Company”) is pleased to announce that an option agreement has been entered into between Vanstar Mining Resources Inc and the Company regarding the Amanda project. C...

MONTREAL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “the Company”) announces that it has acquired from privately held Arlène Explorations Ltd eleven additional new mining cells in the immediate vicinity of the Abra...

MONTREAL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) is pleased to announce the start of prospecting work for critical minerals on the Lichen project after several weeks of delay caused by forest fires. Cove...

MONTREAL, July 25, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) acquired by map staking and from two prospectors the Abrat SM project consisting of 148 cells with an area of ​​approximately 6,590 hectares loc...

Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch Molecure can proceed with clinical trial s in the U.S. A &#...

Press release Molecure completes successful S econdary P ublic O ffering (SPO) of approximately PLN 50 million ( USD 12 million ) with proceeds to be used to fund and build a first in class, sustainable ...

OATD-01 is a first in class chitotriosidase 1 (CHIT1) inhibitor with disease modifying potential in sarcoidosis and other interstitial lung diseases Clearance of the IND application will pave the way for Molecure to initiate the study in the United States becoming only the second Polish b...